Shares of Moleculin Biotech jumped 7.7% to $0.77 on September 14, bucking a broader market selloff, after investors digested encouraging interim data from the company's pivotal late-stage trial of its cancer drug Annamycin — a next-generation chemotherapy designed to kill leukemia cells without the heart damage that limits older treatments.
• The Drug Appears to Work Where Others Fail — Earlier-phase trials showed a 60% complete remission rate in patients whose leukemia had stopped responding to other leading therapies — more than four times higher than published historical rates.
Moleculin describes Annamycin as designed to avoid the drug-resistance problems and heart toxicity common with currently prescribed chemotherapies in its class.
Data presented at the 2026 ASCO meeting showed no detectable heart damage even at doses far exceeding traditional lifetime limits. For patients and investors alike, a potent chemo that doesn't damage the heart could justify repeat treatment cycles — and a premium price tag.
• The Conference Circuit Is Building Momentum — On September 11, Moleculin released its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference.
Today the company announced new Annamycin data will be presented at the AACR pancreatic cancer conference and two European scientific meetings this month,
addressing questions about where the drug concentrates in the body, how it kills cancer, and whether it enlists the immune system. More presentations mean more visibility — critical for a sub-$15 million market-cap name that needs partners or funding to survive.
• Cash Burn Is the Elephant in the Room — Moleculin reported roughly $10.3 million in cash, minimal debt, but a net loss of $12.8 million in its most recent quarter with operating cash outflow near $6.1 million.
The company completed a $9.3 million equity offering in late July,
meaning dilution and future capital raises remain firmly on the table.
H.C. Wainwright maintains a Buy rating but slashed its price target from $22 to $3 in August after the financing dilution.
• The Path Forward Hinges on a Single Trial — The company targets an accelerated FDA application process potentially beginning as early as 2027,
aided by fast-track and orphan drug designations. But with only 17 employees and quarterly losses exceeding its cash balance, every data readout is existential. Today's pop feels justified by the science; sustaining it requires the balance sheet to keep pace.